Richard E Nelson1, Vanessa W Stevens2, Karim Khader3, Makoto Jones3, Matthew H Samore3, Martin E Evans4, R Douglas Scott5, Rachel B Slayton5, Marin L Schweizer6, Eli L Perencevich6, Michael A Rubin3. 1. Veterans Affairs Salt Lake City Health Care System, Salt Lake City, Utah; Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah. Electronic address: richard.nelson@utah.edu. 2. Veterans Affairs Salt Lake City Health Care System, Salt Lake City, Utah; Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, Utah. 3. Veterans Affairs Salt Lake City Health Care System, Salt Lake City, Utah; Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah. 4. Veterans Affairs Medical Center, Lexington, Kentucky; MRSA/MDRO Program, National Infectious Disease Service, Veterans Health Administration, Lexington, Kentucky; Department of Internal Medicine, University of Kentucky, Lexington, Kentucky. 5. Division of Healthcare Quality Promotion, CDC, Atlanta, Georgia. 6. Iowa City Veterans Affairs Health Care System, Iowa City, Iowa; Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, Iowa.
Abstract
INTRODUCTION: In an effort to reduce methicillin-resistant Staphylococcus aureus (MRSA) transmission through universal screening and isolation, the Department of Veterans Affairs (VA) launched the National MRSA Prevention Initiative in October 2007. The objective of this analysis was to quantify the budget impact and cost effectiveness of this initiative. METHODS: An economic model was developed using published data on MRSA hospital-acquired infection (HAI) rates in the VA from October 2007 to September 2010; estimates of the costs of MRSA HAIs in the VA; and estimates of the intervention costs, including salaries of staff members hired to support the initiative at each VA facility. To estimate the rate of MRSA HAIs that would have occurred if the initiative had not been implemented, two different assumptions were made: no change and a downward temporal trend. Effectiveness was measured in life-years gained. RESULTS: The initiative resulted in an estimated 1,466-2,176 fewer MRSA HAIs. The initiative itself was estimated to cost $207 million during this 3-year period, while the cost savings from prevented MRSA HAIs ranged from $27 million to $75 million. The incremental cost-effectiveness ratios ranged from $28,048 to $56,944/life-years. The overall impact on the VA's budget was $131-$179 million. CONCLUSIONS: Wide-scale implementation of a national MRSA surveillance and prevention strategy in VA inpatient settings may have prevented a substantial number of MRSA HAIs. Although the savings associated with prevented infections helped offset some but not all of the cost of the initiative, this model indicated that the initiative would be considered cost effective.
INTRODUCTION: In an effort to reduce methicillin-resistant Staphylococcus aureus (MRSA) transmission through universal screening and isolation, the Department of Veterans Affairs (VA) launched the National MRSA Prevention Initiative in October 2007. The objective of this analysis was to quantify the budget impact and cost effectiveness of this initiative. METHODS: An economic model was developed using published data on MRSA hospital-acquired infection (HAI) rates in the VA from October 2007 to September 2010; estimates of the costs of MRSA HAIs in the VA; and estimates of the intervention costs, including salaries of staff members hired to support the initiative at each VA facility. To estimate the rate of MRSA HAIs that would have occurred if the initiative had not been implemented, two different assumptions were made: no change and a downward temporal trend. Effectiveness was measured in life-years gained. RESULTS: The initiative resulted in an estimated 1,466-2,176 fewer MRSA HAIs. The initiative itself was estimated to cost $207 million during this 3-year period, while the cost savings from prevented MRSA HAIs ranged from $27 million to $75 million. The incremental cost-effectiveness ratios ranged from $28,048 to $56,944/life-years. The overall impact on the VA's budget was $131-$179 million. CONCLUSIONS: Wide-scale implementation of a national MRSA surveillance and prevention strategy in VA inpatient settings may have prevented a substantial number of MRSA HAIs. Although the savings associated with prevented infections helped offset some but not all of the cost of the initiative, this model indicated that the initiative would be considered cost effective.
Authors: Eduardo A F Freitas; Rebecca M Harris; Ruth K Blake; Cassandra D Salgado Journal: Infect Control Hosp Epidemiol Date: 2010-05 Impact factor: 3.254
Authors: Richard E Nelson; Vanessa W Stevens; Makoto Jones; Matthew H Samore; Michael A Rubin Journal: Am J Infect Control Date: 2015-01 Impact factor: 2.918
Authors: Sean D Sullivan; Josephine A Mauskopf; Federico Augustovski; J Jaime Caro; Karen M Lee; Mark Minchin; Ewa Orlewska; Pete Penna; Jose-Manuel Rodriguez Barrios; Wen-Yi Shau Journal: Value Health Date: 2013-12-13 Impact factor: 5.725
Authors: Richard E Nelson; Makoto Jones; Chuan-Fen Liu; Matthew H Samore; Martin E Evans; Nicholas Graves; Bruce Lee; Michael A Rubin Journal: Infect Control Hosp Epidemiol Date: 2015-02-26 Impact factor: 3.254
Authors: Raymund Dantes; Yi Mu; Ruth Belflower; Deborah Aragon; Ghinwa Dumyati; Lee H Harrison; Fernanda C Lessa; Ruth Lynfield; Joelle Nadle; Susan Petit; Susan M Ray; William Schaffner; John Townes; Scott Fridkin Journal: JAMA Intern Med Date: 2013-11-25 Impact factor: 21.873
Authors: Makoto Jones; Jian Ying; Benedikt Huttner; Martin Evans; Matthew Maw; Christopher Nielson; Michael A Rubin; Tom Greene; Matthew H Samore Journal: Clin Infect Dis Date: 2013-10-02 Impact factor: 9.079
Authors: Richard E Nelson; Makoto Jones; Chuan-Fen Liu; Matthew H Samore; Martin E Evans; Vanessa W Stevens; Thomas Reese; Michael A Rubin Journal: Health Serv Res Date: 2018-10-09 Impact factor: 3.402
Authors: Richard E Nelson; Vanessa W Stevens; Makoto Jones; Karim Khader; Marin L Schweizer; Eli N Perencevich; Michael A Rubin; Matthew H Samore Journal: Antimicrob Agents Chemother Date: 2018-10-24 Impact factor: 5.191
Authors: S Ibeneme; V Maduako; G C Ibeneme; A Ezuma; T U Ettu; N F Onyemelukwe; D Limaye; G Fortwengel Journal: Biomed Res Int Date: 2017-06-11 Impact factor: 3.411